SCHEMBL8547834

SCHEMBL8547834

COc1ccc2[nH]c3c(C)c4ccnc(C(=O)NCCN(C)C)c4cc3c2c1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KIT P10721 2/20 0.56
MAPT P10636 4/20 0.47
TP53 P04637 1/20 0.47
SYK P43405 2/20 0.46
BCHE P06276 3/20 0.45
KDM4E B2RXH2 3/20 0.45
MEN1 O00255 3/20 0.45
KMT2A Q03164 3/20 0.45
NPSR1 Q6W5P4 2/20 0.45
RAB9A P51151 2/20 0.45
TLR3 O15455 1/20 0.45
NR3C1 P04150 1/20 0.45
POLB P06746 1/20 0.45
PKM P14618 1/20 0.45
RECQL P46063 1/20 0.45
ACHE P22303 1/20 0.43
DYRK1A Q13627 1/20 0.43
JAK2 O60674 1/20 0.42
BRAF P15056 1/20 0.42
CYP2D6 P10635 2/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9091811 0.95 KIT (0.59) KITMAPTTP53SYKBCHE
SCHEMBL24277000 0.90 KIT (0.54) KITMAPTTP53BCHEKDM4E
SCHEMBL24277001 0.90 KIT (0.57) KITMAPTBCHEKDM4EMEN1
SCHEMBL24276997 0.90 KIT (0.57) KITMAPTBCHEKDM4EMEN1
SCHEMBL24277005 0.89 KIT (0.54) KITMAPTBCHEKDM4EMEN1
Dimethylamine SCHEMBL8545876 0.88 KIT (0.55) KITMAPTBCHEKDM4EMEN1
SCHEMBL8547397 0.88 KIT (0.44) KITKDM4EMEN1KMT2APOLB
Dimethylamine SCHEMBL8547837 0.86 KIT (0.54) KITMAPTBCHEKDM4EMEN1
SCHEMBL9091784 0.84 KDM4E (0.54) KITMAPTTP53SYKBCHE
SCHEMBL24276890 0.84 KIT (0.51) KITMAPTBCHEKDM4EMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240067639-A1 SMALL MOLECULES THAT TARGET THE RNA THAT CAUSES ALS University of Florida Research Foundation, Incorporation (US) 2024-02-29 US disclosed
WO-2022055922-A1 SMALL MOLECULES THAT TARGET THE RNA THAT CAUSES ALS EXPANSION THERAPEUTICS, INC. (US) 2022-03-17 WO disclosed
EP-0591058-B1 Ellipticine derivatives with antitumor activity ADIR (FR) 1998-06-03 EP disclosed
US-5498611-A ANTITUMOR AGENTS ADIR ET COMPAGNIE (FR) 1996-03-12 US disclosed
US-5407940-A Antitumor agents ADIR ET COMPAGNIE (FR) 1995-04-18 US disclosed
EP-0591058-A1 Ellipticine derivatives with antitumor activity ADIR ET COMPAGNIE (FR) 1994-04-06 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240067639-A1 SMALL MOLECULES THAT TARGET THE RNA THAT CAUSES ALS FUS, SNRPE, RRBP1 KIT 4611/4885MAPT 349/4885TP53 820/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.